XRF Scientific (XRF) H2 2025 earnings summary

Executive summary

• Achieved record net profit after tax of $10.4m, up 17% year-over-year, despite a 1% decrease in revenue to $59.5m compared to the prior year.

• Strong performance in Consumables and Orbis Mining, with international sales growth in Asia, Americas, and Europe.

• Fully franked final dividend of 4.5 cents per share declared, a 15% increase over last year.

• Balance sheet remains robust with $12.2m in cash and $1.1m in debt at year-end.

• Completed acquisitions of Labfit and remaining 50% of Orbis Mining, expanding product portfolio and market reach.

Financial highlights

• Revenue decreased 1.1% to $59.5m year-over-year; net profit after tax attributable to members rose 16.9% to $10.4m.

• Operating cash flow increased 25% to $10.1m; EPS up 15% to 7.4 cents.

• Gross profit improved to $28.8m from $26.5m; gross margin increased.

• Final dividend paid was $5.4m; franking credits available at year-end totaled $12.2m.

• Market capitalization at 30 June 2025 was $258.6m, up from $185.8m a year earlier.

Outlook and guidance

• Focus remains on profitability and market capitalization growth through geographic expansion and new product development.

• Ongoing evaluation of acquisition opportunities in adjacent sectors.

• No specific forward-looking financial guidance disclosed due to commercial sensitivity.